Compare Amgen, Inc. (AMGN) vs Target Corporation (TGT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Target Corporation — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Target Corporation trades at $135.7 (market cap $61.38B). The key difference: Amgen, Inc. is far larger — about 3.2× Target Corporation's market cap, and Target Corporation pays the higher dividend (3.43%). Which is the better fit depends on your goals.
| AMGN | TGT | |
|---|---|---|
Market Cap | $196.12B | $61.38B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $141.19 |
52-Week Low | $271.18 | $83.68 |
Enterprise Value | $241.41B | $76.68B |
Dividend Yield | 2.77% | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Target Corporation (TGT) trades at $135.13, up 2.19% with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with a P/E of 17.85, ROE of 22.02%, and positive cash flow trends. Recent corporate restructuring aims to streamline operations while maintaining dividend payments.
Target presents a balanced investment case with solid profitability and analyst consensus near current levels. Upside potential exists toward the $137 price target, though competitive pressures and margin compression remain key risks. The stock offers stability with dividend income but faces retail sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
